$2.01 Billion is the total value of Novo Holdings A/S's 42 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 25.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTI | VANGUARD INDEX FDStotal stk mkt | $522,920,000 | +8.8% | 3,070,400 | 0.0% | 25.96% | -16.3% | |
| AAPL | Buy | APPLE INC | $145,006,000 | +5.1% | 1,252,104 | +231.0% | 7.20% | -19.2% |
| CTLT | Buy | CATALENT INC | $139,283,000 | +130.4% | 1,626,000 | +97.2% | 6.91% | +77.1% |
| HRMY | New | HARMONY BIOSCIENCES HLDGS IN | $127,294,000 | – | 3,754,973 | +100.0% | 6.32% | – |
| CABO | CABLE ONE INC | $108,018,000 | +6.2% | 57,291 | 0.0% | 5.36% | -18.3% | |
| INGN | Sell | INOGEN INC | $102,930,000 | -18.4% | 3,549,320 | -0.0% | 5.11% | -37.2% |
| MDT | MEDTRONIC PLC | $102,687,000 | +13.3% | 988,136 | 0.0% | 5.10% | -12.9% | |
| BAM | BROOKFIELD ASSET MGMT INCcl a ltd vt sh | $101,526,000 | +0.5% | 3,070,957 | 0.0% | 5.04% | -22.7% | |
| NKTX | New | NKARTA INC | $83,984,000 | – | 2,793,864 | +100.0% | 4.17% | – |
| MORF | MORPHIC HLDG INC | $72,326,000 | +1.1% | 2,645,446 | 0.0% | 3.59% | -22.3% | |
| INZY | New | INOZYME PHARMA INC | $67,549,000 | – | 2,569,379 | +100.0% | 3.35% | – |
| MIRM | MIRUM PHARMACEUTICALS INC | $47,118,000 | -1.0% | 2,445,147 | 0.0% | 2.34% | -23.9% | |
| FOLD | AMICUS THERAPEUTICS INC | $32,759,000 | -6.4% | 2,320,026 | 0.0% | 1.63% | -28.0% | |
| PCVX | Sell | VAXCYTE INC | $32,159,000 | +15.4% | 651,255 | -26.2% | 1.60% | -11.3% |
| GRTX | GALERA THERAPEUTICS INC | $30,818,000 | +26.6% | 3,409,021 | 0.0% | 1.53% | -2.6% | |
| CMPI | New | CHECKMATE PHARMACEUTICALS IN | $24,978,000 | – | 2,170,100 | +100.0% | 1.24% | – |
| SPNE | Sell | SEASPINE HLDGS CORP | $23,988,000 | +28.0% | 1,677,492 | -6.3% | 1.19% | -1.6% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $21,783,000 | +8.8% | 234,979 | -8.5% | 1.08% | -16.4% |
| SIBN | Sell | SI BONE INC | $16,569,000 | +5.0% | 698,504 | -29.4% | 0.82% | -19.3% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $15,530,000 | +6.7% | 794,369 | -3.6% | 0.77% | -18.0% |
| MIST | MILESTONE PHARMACEUTICALS IN | $15,230,000 | +93.6% | 2,080,585 | 0.0% | 0.76% | +48.8% | |
| FLXN | FLEXION THERAPEUTICS INC | $14,609,000 | -20.8% | 1,403,370 | 0.0% | 0.72% | -39.1% | |
| INSM | INSMED INC | $13,824,000 | +16.7% | 430,107 | 0.0% | 0.69% | -10.3% | |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $12,672,000 | – | 384,938 | +100.0% | 0.63% | – |
| CNST | Buy | CONSTELLATION PHARMCETICLS I | $11,713,000 | -10.8% | 578,134 | +32.3% | 0.58% | -31.5% |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $11,237,000 | +224.1% | 1,800,747 | +143.1% | 0.56% | +149.1% |
| AKUS | Sell | AKOUOS INC | $10,488,000 | -0.4% | 458,606 | -2.0% | 0.52% | -23.3% |
| SPRO | SPERO THERAPEUTICS INC | $10,391,000 | -17.5% | 931,099 | 0.0% | 0.52% | -36.5% | |
| FRLN | New | FREELINE THERAPEUTICS HLDGSsponsored ads | $10,381,000 | – | 665,000 | +100.0% | 0.52% | – |
| AERI | AERIE PHARMACEUTICALS INC | $9,506,000 | -20.3% | 807,656 | 0.0% | 0.47% | -38.7% | |
| CVAC | New | CUREVAC N V | $9,386,000 | – | 201,642 | +100.0% | 0.47% | – |
| SILK | Sell | SILK RD MED INC | $8,430,000 | +38.4% | 125,428 | -13.8% | 0.42% | +6.4% |
| XENT | Sell | INTERSECT ENT INC | $8,375,000 | +10.8% | 513,515 | -8.1% | 0.42% | -14.8% |
| INSP | Sell | INSPIRE MED SYS INC | $7,697,000 | +11.2% | 59,645 | -25.0% | 0.38% | -14.5% |
| AFIB | New | ACUTUS MED INC | $7,599,000 | – | 255,000 | +100.0% | 0.38% | – |
| ZGNX | ZOGENIX INC | $5,842,000 | -33.6% | 325,814 | 0.0% | 0.29% | -48.9% | |
| CRVS | Sell | CORVUS PHARMACEUTICALS INC | $5,572,000 | -30.0% | 1,389,498 | -52.5% | 0.28% | -46.1% |
| BHVN | BIOHAVEN PHARMACTL HLDG CO L | $5,500,000 | -11.1% | 84,600 | 0.0% | 0.27% | -31.6% | |
| NARI | INARI MED INC | $5,211,000 | +42.5% | 75,500 | 0.0% | 0.26% | +9.7% | |
| AKBA | AKEBIA THERAPEUTICS INC | $4,989,000 | -81.5% | 1,987,506 | 0.0% | 0.25% | -85.8% | |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $4,252,000 | +13.2% | 271,378 | +26.5% | 0.21% | -13.2% |
| ETTX | Sell | ENTASIS THERAPEUTICS HLDGS I | $2,354,000 | -63.5% | 1,153,911 | -47.1% | 0.12% | -71.9% |
| STIM | Exit | NEURONETICS INC | $0 | – | -514,190 | -100.0% | -0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
| SC 13D/A | 2024-03-07 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.